CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 106 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q2 2019. The put-call ratio across all filers is 1.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $199,000 | +54.3% | 100,894 | -2.0% | 0.00% | – |
Q4 2020 | $129,000 | -19.4% | 102,904 | +15.7% | 0.00% | – |
Q3 2020 | $160,000 | -81.3% | 88,914 | -12.7% | 0.00% | -100.0% |
Q2 2020 | $855,000 | +98.8% | 101,864 | +24.3% | 0.00% | 0.0% |
Q1 2020 | $430,000 | -2.5% | 81,971 | +1.4% | 0.00% | 0.0% |
Q4 2019 | $441,000 | +15.4% | 80,851 | +3.1% | 0.00% | 0.0% |
Q3 2019 | $382,000 | -30.0% | 78,442 | -0.5% | 0.00% | 0.0% |
Q2 2019 | $546,000 | +16.4% | 78,837 | +16.7% | 0.00% | 0.0% |
Q1 2019 | $469,000 | +24.1% | 67,529 | +4.4% | 0.00% | 0.0% |
Q4 2018 | $378,000 | +18.5% | 64,689 | +52.9% | 0.00% | 0.0% |
Q3 2018 | $319,000 | +38.7% | 42,310 | -7.0% | 0.00% | – |
Q2 2018 | $230,000 | -11.5% | 45,510 | +6.8% | 0.00% | -100.0% |
Q1 2018 | $260,000 | -1.1% | 42,600 | +15.0% | 0.00% | 0.0% |
Q4 2017 | $263,000 | -19.3% | 37,050 | -18.8% | 0.00% | 0.0% |
Q3 2017 | $326,000 | +15.2% | 45,645 | +1.5% | 0.00% | 0.0% |
Q2 2017 | $283,000 | – | 44,975 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 5,045,870 | $42,335,000 | 24.44% |
MANGROVE PARTNERS IM, LLC | 552,200 | $4,633,000 | 1.13% |
ETF MANAGERS GROUP, LLC | 3,707,912 | $31,109,000 | 1.10% |
Ikarian Capital, LLC | 1,350,000 | $11,327,000 | 0.90% |
GENERAL AMERICAN INVESTORS CO INC | 712,400 | $5,977,000 | 0.76% |
AdvisorShares Investments LLC | 189,814 | $1,593,000 | 0.68% |
Ikarian Capital, LLC | 1,000,000 | $8,390,000 | 0.67% |
Granite Point Capital Management, L.P. | 1,123,600 | $9,427,000 | 0.48% |
Carmignac Gestion | 3,773,440 | $31,659,000 | 0.44% |
Omnia Family Wealth, LLC | 32,356 | $271,467,000 | 0.27% |